News Article Details

Study Focuses on Autism Medication

The Pilot - 8/17/2017

The Centers for Disease Control (CDC) estimates that 1 in 68 children in the U.S. have been identified with autism spectrum disorder (ASD), making the need for treatment of this disorder paramount.

Many children with autism exhibit impaired protein digestion and as result may self-restrict their diets. The inability to digest protein affects the availability of essential amino acids in the body. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters important from brain development.

Curemark, a biotech company based in New York, is developing a potential treatment for Autism that is based on its founder's discovery that many autistic children are deficient in an important enzyme used to digest protein into its building blocks.

The research is a Phase III FDA Fast-Track clinical trial, and accepting patients at Duke Center for Autism and Brain Development.

For more information on the study of a biological autism medication, sponsored by Curemark LLC, call (888) 691-1062 or email autismresearch@duke.edu. Reference IRB number Pro00064746.

More information is also available at http://autismcenter.duke.edu/research/bl%C3%BCm-study-biological-autism-medication.

 
Processing...


Driving   Walking/Biking    Get Directions